ONESOURCE SPECL PHARMA L
Valuation (97/100) does the heavy lifting; financial trend (11/100) is the drag.
Buy zoneONESOURCE SPECL PHARMA L earns a Hold from StocksWizard, with a blended score of 45/100. On 20.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 16% below its 52-week high of ₹1,889.8 and 43% above the low of ₹1,114. Financial health scores 91/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,036.75 implies about 28% upside across 4 analysts. It clears 5 of 14 investability checks, with durability 21, valuation 94 and momentum 38 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,277.38. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-09-1252-week range
-15.75% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -1.3%
- Pass: Low debt (D/E < 0.5): 0.26x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 1%
- Fail: Earnings growing: -95%
- Fail: Net margin ≥ 10%: -5.2%
- Fail: Current ratio > 1.5: 0.99
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- Fail: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.64
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter38.0%
- Institutions33.4%
- Public & other28.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.64.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~79% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (-1.3%).
Threats
- Earnings contracting year on year.
About ONESOURCE SPECL PHARMA L
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices,
ONESOURCE SPECL PHARMA L — frequently asked questions
Is ONESOURCE SPECL PHARMA L a buy, hold or sell?
StocksWizard currently rates ONESOURCE SPECL PHARMA L (ONESOURCE) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is ONESOURCE SPECL PHARMA L's fair value?
Our blended DCF and relative-valuation model estimates ONESOURCE SPECL PHARMA L's fair value at about ₹2,846.72, versus a current price of ₹1,592.2 — roughly 79% upside. On that basis the stock looks undervalued by 79%.
Is ONESOURCE SPECL PHARMA L financially healthy?
ONESOURCE SPECL PHARMA L scores 91/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has ONESOURCE SPECL PHARMA L's share price performed?
ONESOURCE SPECL PHARMA L is down 14% over the past year and roughly flat over three months, and last traded at ₹1,592.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.